Therapeutic Use of Cannabis and Cannabinoids: A Review.
Hsu M, Shah A, Jordan A, Gold MS, Hill KP.
JAMA. 2026 Jan 27;335(4):345-359. doi: 10.1001/jama.2025.19433.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelon S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti E.
BMJ. 2023 Aug 30;382:e072348. doi: 10.1136/bmj-2022-072348.
Association Between Cannabis and Psychosis: Epidemiologic Evidence.
Gage SH, Hickman M, Zammit S.
Biol Psychiatry. 2016 Apr 1;79(7):549-56. doi: 10.1016/j.biopsych.2015.08.001. Epub 2015 Aug 12.
Cannabis use and psychosis: a review of reviews.
Hasan A, von Keller R, Friemel CM, Hall W, Schneider M, Koethe D, Leweke FM, Strube W, Hoch E.
Eur Arch Psychiatry Clin Neurosci. 2020 Jun;270(4):403-412. doi: 10.1007/s00406-019-01068-z. Epub 2019 Sep 28.
Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.
Stanciu CN, Brunette MF, Teja N, Budney AJ.
Psychiatr Serv. 2021 Apr 1;72(4):429-436. doi: 10.1176/appi.ps.202000189. Epub 2021 Feb 3.
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J.
BMC Psychiatry. 2020 Jan 16;20(1):24. doi: 10.1186/s12888-019-2409-8.
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J.
Biomolecules. 2020 Nov 19;10(11):1575. doi: 10.3390/biom10111575.
New Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects.
Taflaj B, La Maida N, Tittarelli R, Di Trana A, D'Acquarica I.
Int J Mol Sci. 2024 Aug 31;25(17):9484. doi: 10.3390/ijms25179484.
Cannabinoids and Psychosis.
D'Souza DC, Radhakrishnan R, Sherif M, Cortes-Briones J, Cahill J, Gupta S, Skosnik PD, Ranganathan M.
Curr Pharm Des. 2016;22(42):6380-6391. doi: 10.2174/1381612822666160826105628.
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S.
Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15.
